Stock RDGL VIVOS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Vivos Inc.

Equities

RDGL

US92858K2042

Market Closed - OTC Markets
Other stock markets
 03:54:15 2024-05-31 pm EDT 		5-day change 1st Jan Change
0.172 USD +1.47% Intraday chart for Vivos Inc. +17.01% +137.90%
May. 09 Vivos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 18 Vivos Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vivos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Vivos Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation
AQ
Vivos Inc. Announces Radiogel(TM) Precision Radionuclide Therapy(TM) Receives FDA Breakthrough Device Designation
CI
Vivos Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Vivos : Quarterly Progress Report - Form 8-K
PU
Vivos Inc. Announces Certification of Three New IsoPet® Precision Radionuclide Therapy Regional Clinics
AQ
Vivos Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
VIVOS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Vivos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
VIVOS INC : Unregistered Sale of Equity Securities (form 8-K)
AQ
VIVOS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)
AQ
Vivos Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Vivos Inc. Auditor Raises 'Going Concern' Doubt
CI
Vivos Inc Files a New Patent on Alternate Particles for Precision Radionuclide Therapy
AQ
Vivos Inc Files A New Patent on Alternate Particles for Precision Radionuclide Therapy
CI
Vivos Inc Files a New Patent on Precision Radionuclide Therapy Support System Equipment
AQ
Vivos Inc. Files New Patent on Precision Radionuclide Therapy Support System Equipment
CI
VIVOS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Vivos Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RDGL Stock
  4. News Vivos Inc.